Cargando…
The factors associated with chronic benzodiazepine use in bipolar patients
INTRODUCTION: Benzodiazepines (BZD) are widely used in patients with bipolar disorder (BD) and their effectiveness is well documented. Therefore, there are major risks associated with BZD use including abuse and dependence. Those risks can be related to the patients’chacteristics, the particularitie...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9528342/ http://dx.doi.org/10.1192/j.eurpsy.2021.539 |
_version_ | 1784801278936743936 |
---|---|
author | Charfi, N. Abdallah, M. Ben Omri, S. Smaoui, N. Feki, R. Thabet, J. Ben Zouari, L. Bouali, M. Maalej Maalej, M. |
author_facet | Charfi, N. Abdallah, M. Ben Omri, S. Smaoui, N. Feki, R. Thabet, J. Ben Zouari, L. Bouali, M. Maalej Maalej, M. |
author_sort | Charfi, N. |
collection | PubMed |
description | INTRODUCTION: Benzodiazepines (BZD) are widely used in patients with bipolar disorder (BD) and their effectiveness is well documented. Therefore, there are major risks associated with BZD use including abuse and dependence. Those risks can be related to the patients’chacteristics, the particularities of BD and the prescribers. OBJECTIVES: To determine the factors associated with chronic use of BZD in patients with BD. METHODS: We conducted a cross-sectional, descriptive and analytical study among a sample of patients with BD (DSM-5) followed in psychiatric outpatient of Hedi Chaker university hospital in Sfax. We used the Benzodiazepine Cognitive Attachment Scale (ECAB) to determine dependent patients RESULTS: Among the 61 included patients, 50 (82%) had a chronic use of BZD (> 3 months). They had a mean age of 49.3 years (± 14.02 years) and a low socio-economic level in 44%. The type of BD was dominated by type II (66%). Initial episode type was depressive in 78%. The average number of depressive episodes was 2.92±2.3. A rate of 65.5% of patients have already attempted BZD withdrawal. Chronic BZD use was significantly correlated with BZD dependence (p=0.000), low socioeconomic level (p=0.04), depressive type of the initial episode (p=0.011), the depressive recurrence (p=0.000) and the absence of any attempt to discontinue BZD (p=0.011). CONCLUSIONS: Chronic use of BZD in patients with BD is prevalent. In order to minimize this problem in this population, it is important to enhance programs to improve psychiatrist-prescribing behavior and to use cognitive-behavioral therapies in combination with medication to help withdrawal. |
format | Online Article Text |
id | pubmed-9528342 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Cambridge University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-95283422022-10-17 The factors associated with chronic benzodiazepine use in bipolar patients Charfi, N. Abdallah, M. Ben Omri, S. Smaoui, N. Feki, R. Thabet, J. Ben Zouari, L. Bouali, M. Maalej Maalej, M. Eur Psychiatry Abstract INTRODUCTION: Benzodiazepines (BZD) are widely used in patients with bipolar disorder (BD) and their effectiveness is well documented. Therefore, there are major risks associated with BZD use including abuse and dependence. Those risks can be related to the patients’chacteristics, the particularities of BD and the prescribers. OBJECTIVES: To determine the factors associated with chronic use of BZD in patients with BD. METHODS: We conducted a cross-sectional, descriptive and analytical study among a sample of patients with BD (DSM-5) followed in psychiatric outpatient of Hedi Chaker university hospital in Sfax. We used the Benzodiazepine Cognitive Attachment Scale (ECAB) to determine dependent patients RESULTS: Among the 61 included patients, 50 (82%) had a chronic use of BZD (> 3 months). They had a mean age of 49.3 years (± 14.02 years) and a low socio-economic level in 44%. The type of BD was dominated by type II (66%). Initial episode type was depressive in 78%. The average number of depressive episodes was 2.92±2.3. A rate of 65.5% of patients have already attempted BZD withdrawal. Chronic BZD use was significantly correlated with BZD dependence (p=0.000), low socioeconomic level (p=0.04), depressive type of the initial episode (p=0.011), the depressive recurrence (p=0.000) and the absence of any attempt to discontinue BZD (p=0.011). CONCLUSIONS: Chronic use of BZD in patients with BD is prevalent. In order to minimize this problem in this population, it is important to enhance programs to improve psychiatrist-prescribing behavior and to use cognitive-behavioral therapies in combination with medication to help withdrawal. Cambridge University Press 2021-08-13 /pmc/articles/PMC9528342/ http://dx.doi.org/10.1192/j.eurpsy.2021.539 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Abstract Charfi, N. Abdallah, M. Ben Omri, S. Smaoui, N. Feki, R. Thabet, J. Ben Zouari, L. Bouali, M. Maalej Maalej, M. The factors associated with chronic benzodiazepine use in bipolar patients |
title | The factors associated with chronic benzodiazepine use in bipolar patients |
title_full | The factors associated with chronic benzodiazepine use in bipolar patients |
title_fullStr | The factors associated with chronic benzodiazepine use in bipolar patients |
title_full_unstemmed | The factors associated with chronic benzodiazepine use in bipolar patients |
title_short | The factors associated with chronic benzodiazepine use in bipolar patients |
title_sort | factors associated with chronic benzodiazepine use in bipolar patients |
topic | Abstract |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9528342/ http://dx.doi.org/10.1192/j.eurpsy.2021.539 |
work_keys_str_mv | AT charfin thefactorsassociatedwithchronicbenzodiazepineuseinbipolarpatients AT abdallahmben thefactorsassociatedwithchronicbenzodiazepineuseinbipolarpatients AT omris thefactorsassociatedwithchronicbenzodiazepineuseinbipolarpatients AT smaouin thefactorsassociatedwithchronicbenzodiazepineuseinbipolarpatients AT fekir thefactorsassociatedwithchronicbenzodiazepineuseinbipolarpatients AT thabetjben thefactorsassociatedwithchronicbenzodiazepineuseinbipolarpatients AT zouaril thefactorsassociatedwithchronicbenzodiazepineuseinbipolarpatients AT boualimmaalej thefactorsassociatedwithchronicbenzodiazepineuseinbipolarpatients AT maalejm thefactorsassociatedwithchronicbenzodiazepineuseinbipolarpatients AT charfin factorsassociatedwithchronicbenzodiazepineuseinbipolarpatients AT abdallahmben factorsassociatedwithchronicbenzodiazepineuseinbipolarpatients AT omris factorsassociatedwithchronicbenzodiazepineuseinbipolarpatients AT smaouin factorsassociatedwithchronicbenzodiazepineuseinbipolarpatients AT fekir factorsassociatedwithchronicbenzodiazepineuseinbipolarpatients AT thabetjben factorsassociatedwithchronicbenzodiazepineuseinbipolarpatients AT zouaril factorsassociatedwithchronicbenzodiazepineuseinbipolarpatients AT boualimmaalej factorsassociatedwithchronicbenzodiazepineuseinbipolarpatients AT maalejm factorsassociatedwithchronicbenzodiazepineuseinbipolarpatients |